Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesElanco Animal Health

Elanco Animal Health

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
26.76 USD -0.08 ( 0.30%)
Last update at 2026-11-10T21:00:00Z
VOLUME
5195784
Market Cap
11487.34M

Momentum Score

…

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
26.33
Low
27.14
High
52 Week Price Range
18.45
Low
27.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Elanco Animal Health develops and sells pharmaceuticals, vaccines and other health products for companion animals and food animals worldwide. Long-term growth may be supported by rising pet ownership, expanding livestock protein demand in emerging markets and product innovation plus integration synergies from prior acquisitions. The company's broad product portfolio and global distribution network may appeal to investors looking for exposure to animal health trends.
Key investment risks include substantial leverage from past acquisitions, pricing and competitive pressure from larger rivals, regulatory approvals and changing animal-health regulations could affect sales and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
26.84
Dividend Yield
-
Revenue TTM
5020.00M
Revenue Per Share
10.09
Gross Profit TTM
2779.00M
Debt / Equity
0.61
ROE
-2.98%
Net Debt
3472.00M
ROCE
-0.03%
Diluted EPS TTM
-0.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -224.00M 488.00M -1195.00M -66.00M -567.00M
Net income -232.00M 338.00M -1231.00M -74.00M -472.00M
Selling general administrative 1430.00M 1072.00M 1073.00M 1266.00M 1404.00M
Selling and marketing expenses - 236.00M 207.00M - -
Gross profit 2050.00M 1909.00M 1938.00M 2505.00M 2631.00M
Reconciled depreciation 680.00M 662.00M 691.00M 528.00M 556.00M
Ebit -4.00M 827.00M -918.00M 358.00M 297.00M
Ebitda 676.00M 1489.00M -224.00M 886.00M 853.00M
Depreciation and amortization 680.00M 662.00M 694.00M 528.00M 556.00M
Non operating income net other - - - -32.00M -5.00M
Operating income 252.00M 251.00M 326.00M 358.00M 297.00M
Other operating expenses 4463.00M 4188.00M 4091.00M 4028.00M 4463.00M
Interest expense 220.00M 339.00M 277.00M 241.00M 236.00M
Tax provision 8.00M 150.00M -13.00M 8.00M -95.00M
Net interest income -220.00M -235.00M -272.00M -241.00M -236.00M
Non recurring - - - 183.00M 628.00M
Income tax expense 8.00M 150.00M 36.00M 8.00M -95.00M
Total revenue 4715.00M 4439.00M 4417.00M 4418.00M 4765.00M
Total operating expenses 1798.00M 1658.00M 1612.00M 2115.00M 2329.00M
Cost of revenue 2665.00M 2530.00M 2479.00M 1913.00M 2134.00M
Total other income expense net -476.00M 237.00M -1521.00M -424.00M -864.00M
Net income from continuing ops -232.00M 338.00M -1144.00M -74.00M -472.00M
Net income applicable to common shares - - - -78.00M -472.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13358.00M 12614.00M 14362.00M 15491.00M 16483.00M
Intangible assets 3408.00M 3681.00M 4494.00M 4842.00M 5587.00M
Other current assets 236.00M 287.00M 310.00M 394.00M 237.00M
Total liab 6811.00M 6518.00M 8139.00M 8202.00M 8945.00M
Total stockholder equity 6547.00M 6096.00M 6223.00M 7289.00M 7538.00M
Other current liab 1155.00M 975.00M 933.00M 924.00M 746.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -2182.00M -1950.00M -2288.00M -1057.00M -949.00M
Other liab - - - 941.00M 1150.00M
Good will 4779.00M 4414.00M 5094.00M 5993.00M 6172.00M
Other assets - - - 193.00M 183.00M
Cash 545.00M 468.00M 352.00M 345.00M 638.00M
Total current liabilities 1597.00M 1315.00M 1241.00M 1702.00M 1643.00M
Current deferred revenue - - 524.00M - 185.00M
Net debt 3472.00M 3853.00M 5422.00M 5491.00M 5681.00M
Short term debt 74.00M 44.00M 38.00M 388.00M 294.00M
Short long term debt 74.00M 44.00M 38.00M 388.00M 294.00M
Short long term debt total 4017.00M 4321.00M 5774.00M 5836.00M 6319.00M
Other stockholder equity 8870.00M 8817.00M 8777.00M 8738.00M 8696.00M
Property plant equipment - - - 999.00M 1222.00M
Total current assets 3458.00M 3215.00M 3407.00M 3279.00M 3276.00M
Net tangible assets - - - -3546.00M -4325.00M
Net receivables 940.00M 886.00M 1010.00M 1002.00M 1028.00M
Long term debt 3943.00M 4277.00M 5736.00M 5448.00M 6025.00M
Inventory 1737.00M 1574.00M 1735.00M 1538.00M 1373.00M
Accounts payable 368.00M 296.00M 270.00M 390.00M 418.00M
Accumulated other comprehensive income -141.00M -771.00M -266.00M -392.00M -209.00M
Retained earnings total equity - - - -1057.00M -949.00M
Non currrent assets other 304.00M 311.00M 315.00M 378.00M 387.00M
Non current assets total 9900.00M 9399.00M 10955.00M 12212.00M 13207.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 1158.00M -210.00M -179.00M -530.00M
Change to liabilities - - - -98.00M -120.00M
Total cashflows from investing activities -279.00M 1158.00M -169.00M -179.00M -530.00M
Net borrowings -563.00M -1475.00M -77.00M -518.00M 241.00M
Total cash from financing activities -275.00M -1492.00M -83.00M -549.00M 210.00M
Change to operating activities - - - -109.00M 31.00M
Net income -232.00M 338.00M -1231.00M -78.00M -472.00M
Change in cash 77.00M 116.00M 7.00M -293.00M 132.00M
Begin period cash flow 468.00M 352.00M 345.00M 638.00M 506.00M
End period cash flow 545.00M 468.00M 352.00M 345.00M 638.00M
Total cash from operating activities 560.00M 541.00M 271.00M 452.00M 483.00M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 680.00M 662.00M 694.00M 682.00M 716.00M
Other cashflows from investing activities -3.00M -14.00M -10.00M -42.00M -8.00M
Change to inventory -57.00M 44.00M -160.00M -269.00M 27.00M
Change to account receivables -12.00M 12.00M -40.00M 14.00M -3.00M
Other cashflows from financing activities 288.00M -17.00M -6.00M 941.00M 1033.00M
Change to netincome - - - 22.00M 326.00M
Capital expenditures 276.00M 147.00M 154.00M 184.00M 197.00M
Change receivables - - - 14.00M -25.00M
Cash flows other operating - - - 179.00M 434.00M
Cash and cash equivalents changes - - - -276.00M 163.00M
Change in working capital 99.00M 149.00M -300.00M -462.00M -87.00M
Stock based compensation 68.00M 55.00M 46.00M 59.00M 66.00M
Other non cash items 79.00M -551.00M 1142.00M 308.00M 414.00M
Free cash flow 284.00M 394.00M 117.00M 268.00M 286.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ELAN
Elanco Animal Health		 -0.08
0.30%		 26.76 - 19.30 2.29 1.76 2.98 19.30
MKKGY
Merck KGaA ADR		 -0.04
0.12%		 33.67 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -0.58
0.34%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16
0.76%		 20.93 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 42.77 - 10.66 0.01 1.16 2.94 23.11

Profile*

Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

450 Elanco Circle, Indianapolis, IN, United States, 46221

877 352 6261

https://www.elanco.com

9400

Name Title Year Born
Mr. Jeffrey N. Simmons Pres, CEO & Director 1967
Mr. Todd S. Young Exec. VP of Corp. Governance and Strategy & CFO 1972
Mr. Ramiro Martin Cabral Exec. VP & Pres of Elanco International 1972
Mr. James M. Meer Sr. VP & Chief Accounting Officer 1970
Mr. Chris Keeley Sr. VP & Chief Information Officer NA
Mr. David S. Kinard Exec. VP of HR Corp. Affairs & Admin. 1967
Ms. Marcela A. Kirberger Exec. VP, Gen. Counsel & Corp. Sec. 1967
Mr. David Alan Urbanek Exec. VP of Manufacturing & Quality 1967
Mr. Shawn McKee Sr. VP of U.S. Companion Animal NA
Mr. Larbi Van Lier Sr. VP of Asia NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…